Franz Hefti, a vice president at Avid Radiopharmaceuticals who used to head neuroscience research at Merck and Genentech, says that at least one large pharma firm has in the last several years quashed a candidate similar to lorcaserin, not because of any science but because of the psychological link to the fen-phen disaster.

FORBES: Magazine Article